You have a lot to protect, bank more than cord blood.

LifebankUSA: Technological Leaders Caring for Your Future

As the only company that offers cord blood, placenta blood and tissue banking - and the first to release placenta-derived stem cells for a successful transplant - we are proud to be technological leaders in a field that is helping so many families, and poised to help countless others.

We enable you to bank more of the stem cells shown to increase transplant success and survival, including CD34+ stem cells, and more mesenchymal-like cells, which may prove to be useful in the emerging field of regenerative medicine. Our strict procedures deliver unsurpassed purity, and you can trust that the stem cells your family banks will be available when you need them most. And you can be secure in the knowledge that our parent company, Celgene Corporation, provides the resources we need to keep doing what we do best: preserving stem cells for generations to come.

If these sound like a lot of benefits, they should. Because no one gives you more lifesaving potential than LifebankUSA.

Learn more about LifebankUSA.

Celgene Corporation: A Solid Foundation

Celgene Corporation is a world-class biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

We believe that a commitment to medical progress achieved through innovative science and life-enhancing new therapies must go hand in hand with a corresponding promise to ensure that patients who can benefit from our discoveries have the opportunity to do so.

Cord blood and placenta-derived stem cells banked with LifebankUSA are indicated for hematopoietic reconstitution (the reformation of blood cellular components) for autologous use or use in first or second degree blood relatives. Any use of cord blood and placental stem cells other than for hematopoietic reconstitution is considered investigational, including regenerative medicine* therapies.

The chance that a child will use his/her own stored stem cells during his/her lifetime for currently treated conditions is estimated at 1 in 400.† These odds may increase if there is a family history of certain blood disorders or cancers. The potential risks and benefits of stem cell transplantation vary and depend on many factors, such as the amount and quality of the stem cells collected, the HLA compatibility between recipient and donor, and the client's overall health. Talk with your health care provider. For more information, call us at 1-877-LIFEBANKUSA ( 1-877-543-3226 ).

*These uses are not consistent with current labeling, are investigational and may never become standard therapy.
† Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14(3):316-322.